What's Happening?
Privo Technologies has announced that its non-surgical therapy, PRV111, has met its primary efficacy endpoint in a Phase 2/3 trial for early-stage non-invasive oral cancer and high-grade dysplasias. The
trial demonstrated a 92% complete response rate, with all patients avoiding surgery. PRV111, a nanoengineered, cisplatin-releasing patch, cleared or downgraded lesions without surgical excision, preserving normal tissue function. The therapy showed durable responses with no recurrences observed over a median follow-up of six months. The treatment was well-tolerated, with mild adverse events and negligible systemic exposure to cisplatin.
Why It's Important?
PRV111 represents a significant advancement in the treatment of non-invasive oral cancers, offering a non-surgical alternative that preserves quality of life by avoiding the complications associated with repeated surgeries. This development could redefine the standard of care for oral precancer and early carcinoma in situ, providing a less invasive option for patients. For the healthcare industry, this innovation highlights the potential of localized therapies to improve patient outcomes and reduce healthcare costs associated with surgical interventions.
What's Next?
Privo Technologies plans to initiate a registrational study of PRV111 in non-invasive oral cancers and high-grade dysplasias. The company will also explore the application of PRV111 in other early malignant and premalignant lesions. As the therapy progresses towards potential regulatory approval, stakeholders, including patients, healthcare providers, and investors, will be watching closely for further developments and clinical trial results.
